Buy IBM as investors underappreciate the strength of its software business, says JPMorgan

JPMorgan upgraded IBM to overweight from neutral and raised its price target to $291 from $270, implying 15% upside from Monday's close. The bank sees IBM's software business as an underappreciated growth driver, now representing roughly 45% of revenue and about two-thirds of consolidated profit, with better margins, cash flow, and earnings quality. The call reinforces a generally positive Street view, though the stock is still down nearly 15% year to date.

Analysis

The key signal is not that IBM software is “good,” but that the market is still valuing it too much like a slow-growth legacy stack instead of a recurring-revenue compounder. If software is already the majority of profit, small improvements in mix and retention can drive outsized EPS and FCF acceleration because the denominator—lower-margin services and infrastructure—doesn’t need to grow fast for the equity to re-rate. That creates a subtle setup where modest mid-single-digit software growth can translate into double-digit earnings power if operating leverage holds.

The second-order winner is likely IBM’s capital allocation flexibility: stronger cash conversion supports buybacks and investment without stressing the balance sheet, which can keep the multiple floor intact even if top-line growth is merely decent. Competitively, the pressure falls on lower-quality enterprise software vendors and services-heavy IT consultancies whose economics look inferior on both margin and recurring visibility. If IBM’s software flywheel is real, it can also make the infrastructure layer more strategically sticky, raising switching costs and slowing share loss in adjacent enterprise workloads.

The risk is timing. This is a 6-12 month catalyst story, not an immediate momentum trade: the market may wait for evidence of acceleration in 2H'26 guidance before re-rating the stock materially. The biggest reversal risk is that software growth is already fully embedded in consensus while services or infrastructure drags offset the margin benefit, leaving IBM with “good quality, mediocre growth” and no multiple expansion. At current levels, the stock likely needs either sustained software upside or a clearer path to buyback-enhanced EPS beats to push through resistance.

The contrarian view is that the opportunity may be less about underappreciated quality and more about an aging franchise that is finally being recognized as a cash machine, which reduces upside from here. If the Street is already broadly positive, the edge is in relative expression: IBM can outperform on resilience, but it may not deliver the kind of re-rating multiple expansion that justifies an outright aggressive long unless the next two quarters show accelerating bookings and durable margin uplift.

Key Decisions for Investors

• Go long IBM on weakness into the next earnings cycle, targeting a 6-12 month hold; the setup favors low-teens upside if software margins and cash flow continue to inflect, with downside protected by cash generation and buybacks.
• Express the view as a pair: long IBM / short a basket of lower-quality enterprise software or services-heavy IT names over the next 3-6 months; the spread should work if investors pay up for recurring revenue quality and penalize weaker conversion.
• Use call spreads in IBM rather than outright stock for the catalyst window (9-12 months out); this keeps theta manageable if the market waits for proof until later in the year while preserving upside to a re-rate.
• Add only on confirmation: if IBM shows evidence of software acceleration in the next two quarters, increase size by 25-50%; if not, treat the thesis as a yield-plus compounder rather than a high-conviction growth rerating story.